Recent Advances in Bladder Cancer Chemotherapy

REFERENCES

• Landis S. H., Murray T., Bolden S., et al. Cancer Statistics, 1999. CA Cancer J. Clin. 1999; 49: 8–31
   PubMed Web of Science ®Google Scholar
• Sternberg C. N., Yagoda A., Scher H. I., et al. Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Advanced Transitional Cell Carcinoma of the Urothelium: Efficacy and Patterns of Response and Relapse. Cancer 1989; 64: 2448–2458
   PubMed Web of Science ®Google Scholar
• Loehrer P. J., Sr., Einhorn L. H., Elson P. J., et al. A Randomized Comparison of Cisplatin Alone or in Combination with Methotrexate, Vinblastine, and Doxorubicin in Patients with Metastatic Urothelial Carcinoma: A Cooperative Group study. J. Clin. Oncol. 1992; 10: 1066–1073
   PubMed Web of Science ®Google Scholar
• Logothetis C. J., Dexeus F. H., Finn L., et al. A Prospective Randomized Trial Comparing MVAC and CISCA Chemotherapy for Patients with Metastatic Urothelial Tumors. J. Clin. Oncol. 1990; 8: 1050–1055
   PubMed Web of Science ®Google Scholar
• Gabrilove J. L., Jakubowski A., Scher H., et al. Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional Cell Carcinoma of the Urothelium. N. Engl. J. Med. 1988; 318: 1414–1422
   PubMed Web of Science ®Google Scholar
• Moore M. J., Iscoe N., Tannock I. F. A Phase II Study of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Plus Human Granulocyte-Macrophage Colony Stimulating Factor in Patients with Advanced Transitional Cell Carcinoma. J. Urol. 1993; 150: 1131–1134
   PubMed Web of Science ®Google Scholar
• Seidman A. D., Scher H., Gabrilove J. L., et al. Dose-Intensification of MVAC with Recombinant Granulocyte Colony-Stimulating Factor as Initial Therapy in Advanced Urothelial Carcinoma. J. Clin. Oncol. 1993; 11: 408–414
   PubMed Web of Science ®Google Scholar
• Loehrer P. J., Sr., Elson P., Dreicer R., et al. Escalated Dosages of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Plus Recombinant Human Granulocyte Colony-Stimulating Factor in Advanced Bladder Carcinoma: An Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 1994; 12: 483–488
   PubMed Web of Science ®Google Scholar
• Logothetis C. J., Finn L. D., Smith T., et al. Escalated MVAC with or Without Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for the Initial Treatment of Advanced Malignant Urothelial Tumors: Results of a Randomized Trial. J. Clin. Oncol. 1995; 13: 2272–2277
   PubMed Web of Science ®Google Scholar
• Bajorin D. F., Dodd P. M., McCaffrey J. A., et al. M-VAC in Transitional Cell Carcinoma (TCC): Prognostic Factors and Long-Term Survival in 203 Patients (pts). Proc. Am. Soc. Clin. Oncol. 1998; 17: 311a, (abstract)
   Google Scholar
• Saxman S. B., Propert K. J., Einhorn L. H., et al. Long-term Follow-up of a Phase III Intergroup Study of Cisplatin Alone or in Combination with Methotrexate, Vinblastine, and Doxorubicin in Patients with Metastatic Urothelial Carcinoma: A Cooperative Group Study. J. Clin. Oncol. 1997; 15: 256–2569
   Google Scholar
• Neill H. B., Rangel C., Miller A., et al. The Activity of Antimicrotubular Agents in Human Bladder Cancer Cell Lines. Proc. Am. Assoc. Cancer Res. 1993; 34: 202, (abstract)
   Google Scholar
• Roth B. J., Dreicer R., Einhorn L. H., et al. Significant Activity of Paclitaxel in Advanced Transitional Cell Carcinoma of the Urothelium: A Phase II Trial of the Eastern Cooperative Oncology Group (E1892). J. Clin. Oncol. 1994; 12: 2264–2270
   PubMed Web of Science ®Google Scholar
• Waxman J., Barton C. Carboplatin-based Chemotherapy for Bladder Cancer. Cancer Treat. Rev. 1993; 19(suppl C)21–25
   PubMedGoogle Scholar
• Calvert A. H., Newell D. R., Grumbell L. A., et al. Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function. J. Clin. Oncol. 1989; 7: 1748–1756
   PubMed Web of Science ®Google Scholar
• Vaughn D. J., Malkowicz S. B., Zoltick B., et al. Paclitaxel Plus Carboplatin in Advanced Carcinoma of the Urothelium: An Active and Tolerable Outpatient Regimen. J. Clin. Oncol. 1998; 16: 255–260
   PubMed Web of Science ®Google Scholar
• Redman B. G., Smith D. C., Flaherty L., et al. Phase II Trial of Paclitaxel and Carboplatin in the Treatment of Advanced Urothelial Carcinoma. J. Clin. Oncol. 1998; 16: 1844–1848
   PubMed Web of Science ®Google Scholar
• Zielinski C. C., Schnack B., Grbovic M., et al. Paclitaxel Plus Carboplatin in Patients with Metastatic Urothelial Cancer: Results of a Phase II Trial. Br. J. Cancer 1998; 78: 370–374
   PubMed Web of Science ®Google Scholar
• Droz J. P., Mottet N., Prapotrich D., et al. Phase II Study of Taxol (Paclitaxel) and Carboplatin in Patients with Advanced Transitional Cell Carcinoma of the Urothelium: Preliminary Results. Proc. Am. Soc. Clin. Oncol. 1998; 17: 316a, (abstract)
   Google Scholar
• Small E. J., Lew D., Petrylak D. P., et al. Carboplatin and Paclitaxel (Carbo/Tax) for Advanced Transitional Cell Carcinoma (TCC) of the Urothelium. Proc. Am. Soc. Clin. Oncol. 1999; 18: 333a, (abstract)
   Google Scholar
• Dreicer R., Roth B., Lipsitz S., et al. E2895 Cisplatin and Paclitaxel in Advanced Carcinoma of the Urothelium: A Phase II Trial of the Eastern Cooperative Oncology Group (ECOG). Proc. Amer. Soc. Clin. Oncol. 1998; 17: 320a, (abstract)
   Google Scholar
• Burch P. A., Richardson R. L., Cha S. S., et al. Phase II Trial of Paclitaxel and Cisplatin in Advanced Urothelial Cancer (UC). Proc. Am. Soc. Clin. Oncol. 1999; 18: 329a, (abstract)
   Google Scholar
• Bajorin D. F., McCaffrey J. A., Hilton S., et al. Treatment of Patients with Transitional-Cell Carcinoma of the Urothelial Tract with Ifosfamide, Paclitaxel, and Cisplatin: A Phase II Trial. J. Clin. Oncol. 1998; 16: 2722–2727
   PubMed Web of Science ®Google Scholar
• McCaffrey J. A., Dodd P. M., Hilton S., et al. Ifosfamide + paclitaxel + Cisplatin (ITP) Chemotherapy for Patients (pts) with Unresectable or Metastatic Transitional Cell Carcinoma (TCC). Proc. Am. Soc. Clin. Oncol. 1999; 18: 329a, (abstract)
   Google Scholar
• Dodd P. M., McCaffrey J. A., Hilton S., et al. Phase I Evaluation of Sequential Doxorubicin + Gemcitabine (AG) then Ifosfamide + Paclitaxel + Cisplatin (ITP) for Patients (pts) with Unresectable or Metastatic Transitional Cell Carcinoma (TCC). Proc. Am. Soc. Clin. Oncol. 1999; 18: 330a, (abstract)
   Google Scholar
• McCaffrey J. A., Hilton S., Mazumdar M., et al. Phase II Trial of Docetaxel in Patients with Advanced or Metastatic Transitional-Cell Carcinoma. J. Clin. Oncol. 1997; 15: 1853–1857
   PubMed Web of Science ®Google Scholar
• deWit R., Kruit W. H.J., Stotler G., et al. Docetaxel (Taxotere): An Active Agent in Metastatic Urothelial Cancer; Results of a Phase II Study in Non-Chemotherapy-Pretreated Patients. Br. J. Cancer 1998; 78: 1342–1345
   PubMed Web of Science ®Google Scholar
• Sengelov L., Kamby C., Lund B., et al. Docetaxel and Cisplatin in Metastatic Urothelial Cancer: A Phase II Study. J. Clin. Oncol. 1998; 16: 3392–3397
   PubMed Web of Science ®Google Scholar
• Vogelzang N. J., Stadler W. M. Gemcitabine and Other New Chemotherapeutic Agents for the Treatment of Metastatic Bladder Cancer. Urology 1999; 53: 243–250
   PubMed Web of Science ®Google Scholar
• Pollera C. F., Cetibelli A., Crecco M., et al. Weekly Gemcitabine in Advanced Bladder Cancer: A Preliminary Report from Phase I study. Ann. Oncol. 1994; 5: 182–184
   PubMed Web of Science ®Google Scholar
• Lorusso V., Pollera C. F., Antimi M., et al. A Phase II Study of Gemcitabine in Patients with Transitional Cell Carcinoma of the Urinary Tract Previously Treated with Platinum. Eur. J. Cancer 1998; 34: 1208–1212
   PubMed Web of Science ®Google Scholar
• Stadler W. M., Kuzel T., Roth B., et al. Phase II Study of Single Agent Gemcitabine in Previously Untreated Patients with Metastatic Urothelial Cancer. J. Clin. Oncol. 1997; 15: 3394–3398
   PubMed Web of Science ®Google Scholar
• Moore M. J., Tannock I. F., Ernst D. S., et al. Gem-scitabine: A Promising New Agent in the Treatment of Advanced Urothelial Cancer. J. Clin. Oncol. 1997; 15: 3441–3445
   PubMed Web of Science ®Google Scholar
• Von der Masse H., Anderson L., Crino L., et al. A Phase II Study of Gemcitabine and Cisplatin in Patients with Transitional Cell Carcinoma (TCC) of the Urothelium. Proc. Am. Soc. Clin. Oncol. 1997; 16: 324a, (abstract)
   Google Scholar
• Moore M. J., Tannock I., Winquist E., et al. Gemcitabine (G) + Cisplatin (C): An Active Regimen in Advanced Transitional Cell Carcinoma (TCC). Proc. Am. Soc. Clin. Oncol. 1998; 17: 320a, (abstract)
   Google Scholar
• Kaufman D., Stadler W., Carducci M., et al. Gemcitabine (gem) Plus Cisplatin (CDDP) in Metastatic Transitional Cell Carcinoma (TCC): Final Results of a Phase II Study. Proc. Am. Soc. Clin. Oncol. 1998; 17: 320a, (abstract)
   Google Scholar
• Einhorn L. H., Raghavan D., Kindler H., et al. A Phase I Trial of Gemcitabine Plus Paclitaxel Combination Therapy in Patients with Refractory Solid Tumors. Proc. Am. Soc. Clin. Oncol. 1998; 17: 207a, (abstract)
   Google Scholar
• Bellmunt J., Guillem V., Paz-Ares L., et al. A Phase II Trial of Paclitaxel, Cisplatin, and Gemcitabine (TCG) in Patients (Pts) with Advanced Transitional Cell Carcinoma (TCC) of the Urothelium. Proc. Am. Soc. Clin. Oncol. 1999; 18: 332a, (abstract)
   Google Scholar
• Vaishampayan U., Smith D., Redman B., et al. Phase II Evaluation of Carboplatin, Paclitaxel, and Gemcitabine in Advanced Urothelial Carcinoma. Proc. Am. Soc. Clin. Oncol. 1999; 18: 333a, (abstract)
   Google Scholar
• Dimopoulos M. A., Moulopoulos L. A. Role of Adjuvant Chemotherapy in the Treatment of Bladder Cancer. J. Clin. Oncol. 1998; 16: 1601–1612
   PubMed Web of Science ®Google Scholar
• Bajorin D. F. Urothelial Carcinoma: Adjuvant and Neoadjuvant Chemotherapy. ASCO Educational Book (Spring). 1998; 317–324
   Google Scholar
• Skinner D. G., Daniels J. R., Russell C. A., et al. The Role of Adjuvant Chemotherapy Following Cystectomy for Invasive Bladder Cancer: A Prospective Comparative Trial. J. Urol. 1991; 145: 459–464
   PubMed Web of Science ®Google Scholar
• Stockle M., Wellek S., Meyenberg W., et al. Radical Cystectomy with or Without Adjuvant Polychemotherapy for Non-Organ Confined Transitional Cell Carcinoma of the Urinary Bladder: Prognostic Impact of Lymph Node Involvement. Urology 1996; 48: 868–875
   PubMed Web of Science ®Google Scholar
• Hall R. Neoadjuvant CMV Chemotherapy and Cystectomy or Radiation in Muscle-Invasive Bladder Cancer: First Analysis of MRC/EORTC Intercontinental Trial. Proc. Am. Soc. Clin. Oncol. 1997; 15: 612, (abstract)
   Google Scholar
• Stein J. P., Grossfeld G. D., Ginsberg D. A., et al. Prognostic Markers in Bladder Cancer: A Contemporary Review of the Literature. J. Urol. 1998; 160: 645–659
   PubMed Web of Science ®Google Scholar
• Chang F., Syrjanen S., Syrjanen K. Implications of the p53 Tumor-Suppressor Gene in Clinical Oncology. J. Clin. Oncol. 1995; 13: 1009–1022
   PubMed Web of Science ®Google Scholar
• Esrig D., Spruck C. H., Nichols P. W., et al. p53 Nuclear Protein Accumulation Correlates with Mutations in the p53 Gene, Tumor Grade, and Stage in Bladder Cancer. Am. J. Pathol. 1993; 143: 1389–1397
   PubMed Web of Science ®Google Scholar
• Vet J. A., Bringuier P. P., Schaafsma E., et al. Comparison of p53 Protein Overexpression with p53 Mutation in Bladder Cancer: Clinical and Biological Aspects. Lab. Invest. 1995; 73: 837–843
   PubMed Web of Science ®Google Scholar
• Esrig D., Elmajian D., Groshen S., et al. Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer. N. Engl. J. Med. 1994; 331: 1259–1264
   PubMed Web of Science ®Google Scholar
• Lipponen P. K. Over-Expression of the p53 Nuclear Oncoprotein in Transitional Cell Carcinoma of the Bladder and its Prognostic Value. Int. J. Cancer 1993; 53: 365–370
   PubMed Web of Science ®Google Scholar
• El-Deiry W., Tokino T., Velculescu V. E., et al. WAF1, a Potential Mediator of p53 Tumor Suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Michieli P., Chedid M., Lin D., et al. Induction of WAF1/CIP1 by a p53-Independent Pathway. Cancer Res. 1994; 54: 3391–3395
   PubMed Web of Science ®Google Scholar
• Stein J. P., Ginsberg D. A., Grossfeld G. D., et al. Effect of p21 (WAF1/CIP1) Expression on Tumor Progression in Bladder Cancer. J. Natl. Cancer Inst. 1998; 90: 1072–1079
   PubMed Web of Science ®Google Scholar
• Sarkis A., Bajorin D. F., Reuter V. E., et al. Prognostic Value of p53 Nuclear Overexpression in Patients with Invasive Bladder Cancer Treated with Neoadjuvant MVAC. J. Clin. Oncol. 1995; 13: 1384–1390
   PubMed Web of Science ®Google Scholar
• Cote R. J., Esrig D., Groshen S., et al. P53 and Treatment of Bladder Cancer. Nature 1997; 385: 123–124
   PubMed Web of Science ®Google Scholar
• Wagner U., Moch H., Kononen J., et al. Evaluation of Prognostic Markers in Urinary Bladder Cancer Using Tumor Tissue Arrays. J. Urol. 1999; 161(suppl)174
   Google Scholar